BioAtla (BCAB) Short Interest Ratio & Short Volume → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free BCAB Stock Alerts $2.71 -0.20 (-6.87%) (As of 05/10/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media BioAtla Short Interest DataCurrent Short Volume5,330,000 sharesPrevious Short Volume5,420,000 sharesChange Vs. Previous Month-1.66%Dollar Volume Sold Short$12.02 millionShort Interest Ratio / Days to Cover8.8Last Record DateApril 30, 2024Outstanding Shares48,100,000 sharesPercentage of Shares Shorted11.08%Today's Trading Volume614,423 sharesAverage Trading Volume751,521 sharesToday's Volume Vs. Average82% Short Selling BioAtla ? Sign up to receive the latest short interest report for BioAtla and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatBCAB Short Interest Over TimeBCAB Days to Cover Over TimeBCAB Percentage of Float Shorted Over Time Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. BioAtla Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20245,330,000 shares $12.02 million -1.7%N/A8.8 $2.26 4/15/20245,420,000 shares $15.50 million -3.0%N/A10.1 $2.86 3/31/20245,590,000 shares $19.23 million +9.0%N/A10.9 $3.44 3/15/20245,130,000 shares $12.52 million +0.4%N/A11.6 $2.44 2/29/20245,110,000 shares $13.80 million +1.4%N/A11 $2.70 2/15/20245,040,000 shares $13.36 million +6.6%N/A9.6 $2.65 Get the Latest News and Ratings for BCAB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter. 1/31/20244,730,000 shares $9.06 million -3.3%N/A9.5 $1.92 1/15/20244,890,000 shares $11.78 million +4.7%N/A9.5 $2.41 12/31/20234,670,000 shares $11.49 million +4.7%N/A9.5 $2.46 12/15/20234,460,000 shares $9.41 million +0.2%N/A9.6 $2.11 11/30/20234,450,000 shares $7.88 million +8.0%N/A10.9 $1.77 11/15/20234,120,000 shares $6.63 million +1.0%N/A12.1 $1.61 10/31/20234,080,000 shares $6.00 million -7.3%N/A13.9 $1.47 10/15/20234,400,000 shares $7.26 million -5.2%N/A17.5 $1.65 9/30/20234,640,000 shares $7.89 million -6.8%N/A20.1 $1.70 9/15/20234,980,000 shares $10.36 million +2.1%N/A20.7 $2.08 8/31/20234,880,000 shares $12.25 million +3.2%N/A13.6 $2.51 8/15/20234,730,000 shares $12.91 million +1.9%N/A12.1 $2.73 7/31/20234,640,000 shares $13.87 million -1.1%N/A11.1 $2.99 7/15/20234,690,000 shares $12.66 million +1.5%N/A10.7 $2.70 6/30/20234,620,000 shares $13.86 million +25.9%N/A8.7 $3.00 6/15/20233,670,000 shares $13.73 million +1.7%N/A6.1 $3.74 5/31/20233,610,000 shares $11.37 million +0.6%N/A7.3 $3.15 5/15/20233,590,000 shares $13.89 million -5.0%N/A7.2 $3.87 4/30/20233,780,000 shares $12.74 million +16.7%N/A7.4 $3.37 4/15/20233,240,000 shares $11.66 million -10.3%N/A5.7 $3.60 3/31/20233,610,000 shares $9.67 million +10.4%N/A4.5 $2.68 3/15/20233,270,000 shares $8.37 million -0.6%N/A4.6 $2.56 2/28/20233,290,000 shares $9.80 million +13.8%N/A4.8 $2.98 2/15/20232,890,000 shares $9.88 million -0.3%N/A4.3 $3.42 1/31/20232,900,000 shares $10.99 million -10.8%N/A3.3 $3.79 1/15/20233,250,000 shares $11.25 million -21.9%N/A3.7 $3.46 12/30/20224,160,000 shares $34.32 million +2.2%N/A6.4 $8.25 12/15/20224,070,000 shares $36.51 million -5.1%N/A7.5 $8.97 11/30/20224,290,000 shares $47.23 million -3.6%N/A7.7 $11.01 11/15/20224,450,000 shares $39.16 million +10.2%N/A8 $8.80 10/31/20224,040,000 shares $27.84 million -20.6%N/A3.5 $6.89 10/15/20225,090,000 shares $35.07 million -1.0%N/A5.4 $6.89 9/30/20225,140,000 shares $39.58 million +27.5%N/A5.2 $7.70 9/15/20224,030,000 shares $34.46 million +7.8%N/A3.7 $8.55He Is Giving Away Bitcoin (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here BCAB Short Interest - Frequently Asked Questions What is BioAtla's current short interest? Short interest is the volume of BioAtla shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 5,330,000 shares of BCAB short. Learn More on BioAtla's current short interest. What is a good short interest ratio for BioAtla? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BCAB shares currently have a short interest ratio of 9.0. Learn More on BioAtla's short interest ratio. Which institutional investors are shorting BioAtla? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of BioAtla: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is BioAtla's short interest increasing or decreasing? BioAtla saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 5,330,000 shares, a drop of 1.7% from the previous total of 5,420,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does BioAtla's short interest compare to its competitors? Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to BioAtla: Cardiff Oncology, Inc. (9.88%), Scilex Holding (8.38%), Cardiol Therapeutics Inc. (0.50%), Molecular Partners AG (0.15%), Vaxart, Inc. (10.44%), DBV Technologies S.A. (0.28%), Cellectis S.A. (1.18%), Genfit S.A. (0.18%), Vigil Neuroscience, Inc. (4.61%), Omega Therapeutics, Inc. (22.04%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short BioAtla stock? Short selling BCAB is an investing strategy that aims to generate trading profit from BioAtla as its price is falling. BCAB shares are trading down $0.20 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against BioAtla? A short squeeze for BioAtla occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BCAB, which in turn drives the price of the stock up even further. How often is BioAtla's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BCAB, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Cardiff Oncology Short Interest Scilex Short Interest Cardiol Therapeutics Short Interest Molecular Partners Short Interest Vaxart Short Interest DBV Technologies Short Interest Cellectis Short Interest Genfit Short Interest Vigil Neuroscience Short Interest Omega Therapeutics Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BCAB) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithCollapse of the Petrodollar Colonial MetalsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings